RB1 and Familial prostate cancer: We found that JKE-1674 treatment significantly extended median overall survival of PPR-RFP mice from 42 to 49 weeks (Figure 5F), further corroborating the potent antitumor and antimetastatic activity exhibited by ferroptosis against RB1-deficient prostate cancer.